Pathios Therapeutics

About Pathios Therapeutics

Pathios Therapeutics is an early-stage drug discovery company that was established in 2017 by a team of experienced pharmaceutical industry professionals and biotech entrepreneurs. Based in Oxford, UK, the company is founded upon a deep understanding of the biology of acid-sensing GPCRs in Th17 cells and tumour-associated macrophages (TAMs). We are currently engaged in a fully-enabled drug discovery program to identify novel small-molecule modulators of GPR65 with expected utility in a range of autoimmune conditions as well as in certain cancers. We are also more broadly interested in acid-sensing receptors in the immune system and their potential exploitation as targets for bringing about therapeutic benefit in a range of diseases.

Pathios employs a cutting edge scientific approach to mapping the signalling of key GPCRs on immune cells based on human genetic insights, transcriptomics and state-of-the-art cellular immunology. By leveraging a range of proprietary insights emerging from this approach Pathios aims to rapidly deliver on the promise of novel therapeutic agents targeting these receptors. We combine a team of experienced scientific leaders with a number of strategic external partnerships to efficiently carry out a range of drug discovery and scientific activities, capitalising on the very latest advances in GPCR drug discovery.